phosphotyrosine has been researched along with carmustine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chee, SK; Hung, H; Hung, NT; Lawrence, P; Pierce, CK | 1 |
| Bahlis, N; Mansoor, A; Stewart, DA | 1 |
2 other study(ies) available for phosphotyrosine and carmustine
| Article | Year |
|---|---|
SarCNU-induced G2/M arrest in hepatoma cells is mediated by a p53-independent phosphorylation of cdc-2 at Tyr15.
Topics: Carmustine; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase; Humans; Liver Neoplasms; Mitosis; Phosphorylation; Phosphotyrosine; Tumor Suppressor Protein p53 | 2005 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Protein Processing, Post-Translational; STAT3 Transcription Factor; Transplantation, Autologous; Tumor Suppressor Protein p53; Vincristine | 2009 |